CIG方案治疗急性髓系白血病疗效分析

Outcome of CIG regiment for treatment of acute myeloid leukemia

关键词:  白血病  髓细胞性  急性  治疗方案

Key words:  leukemia  acute  myeloid  regiment

摘要:

目的观察阿糖胞苷(Ara-C)、去甲氧柔红霉素(IDA)和粒细胞集落刺激因子(G-CSF)联合方案(CIG方案)治疗急性髓系白血病(acute myeloid leukemia,AML)的临床疗效及不良反应。方法初治、难治/复发和老年AML患者中36例采用CIG方案治疗,完成1个疗程后评估疗效,治疗失败患者则退出观察,有效者继续接受1个疗程治疗。随访分析患者总体生存期(overall survival,OS),评判CIG方案的疗效。结果CIG组36例中完全缓解(completely remission,CR)20例(55.5%),部分缓解(partial remission,PR)9例(25%),未缓解(non remission,NR)7例,死亡1例,总有效率80.55%。其中第1个疗程达CR者14例,第2个疗程达CR者6例。CIG组中位OS 26个月。结论初治、难治/复发和老年AML患者治疗中,CIG方案是有效且不良反应低的治疗方法。

Abstract:

Objective To evaluate the efficacy and adverse events of CIG regiment(Ara-C,IDA and G-CSF) in treatment of untreated acute myeloid leukemia(AML),refractory AML/relapsed AML and elderly AML.Methods CIG regiment was used to treat 36 cmases of acute myeloid leukemia.The outcome was evaluated after 1 cmourse of treatment.The patients for whom treatment has failed were exited from the trial and the responders continued to receive another course of treatment.Patients were followed up,overall survival(OS) were analyzed.Results For patients with CIG,20 cases achieved completely remission(CR),9 cases achieved partial remission(PR), The total response rate was 80.55%.14 cases were CR after the first course,6 cases were CR after the second course.The median OS was 26 months.Conclusion Treatment for previously untreated acute myeloid leukemia(AML),refractory AML/relapsed AML and eldly AML with CIG regiment is safe and effective.